MannKind reported $367.44M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Adma Biologics USD 83.12M 702K Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Eli Lilly USD 42.5B 3.6M Dec/2025
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Insmed USD 727.62M 275K Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
MannKind USD 367.44M 247.53M Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 233.31M 4.23M Sep/2024
Novo Nordisk DKK 118.72B 15.94B Mar/2025
Pfizer USD 63.73B 231M Mar/2026
Sanofi EUR 20.33B 1.43B Dec/2025
Xencor USD 187.75M 118.48M Dec/2025